Yatiri Bio
Yatiri Bio is revolutionizing drug discovery by integrating proteomics, deep learning, and patient data to improve clinical development and patient outcomes. The company focuses on developing novel tools for analyzing proteins as functional drivers of disease, facilitating the discovery of therapeutic signatures, and predicting patient outcomes to match individualized therapeutics, aiming to transform current medical practices.
Industries
Nr. of Employees
small (1-50)
Products
Yatiri Bio’s AML Platform
An AI-driven platform combining deep proteomics with living patient-derived models to map disease biology, drug response, and predict clinical trial outcomes for AML.
Yatiri Bio Therapeutic Development Platform
An integrated platform that anchors therapeutic development in real patient biology captured through deep proteomics and translated via machine learning.
ProteoCharts
A proprietary platform used to extract robust therapeutic signatures and companion biomarkers that are clinically actionable.
ProteoModels
Tailored drug discovery efficacy models including cell lines and organoids representing specific molecularly defined subsets of oncology patients.
Global Proteomics
Global proteomics services using high-resolution mass spectrometry on multiple sample types to measure proteins and peptides quantitatively.
ProteoBrowser
Interactive data portal allowing users to interrogate proteomics data in the context of proprietary and public databases.
Yatiri Bio’s AML Platform
An AI-driven platform combining deep proteomics with living patient-derived models to map disease biology, drug response, and predict clinical trial outcomes for AML.
Yatiri Bio Therapeutic Development Platform
An integrated platform that anchors therapeutic development in real patient biology captured through deep proteomics and translated via machine learning.
ProteoCharts
A proprietary platform used to extract robust therapeutic signatures and companion biomarkers that are clinically actionable.
ProteoModels
Tailored drug discovery efficacy models including cell lines and organoids representing specific molecularly defined subsets of oncology patients.
Global Proteomics
Global proteomics services using high-resolution mass spectrometry on multiple sample types to measure proteins and peptides quantitatively.
ProteoBrowser
Interactive data portal allowing users to interrogate proteomics data in the context of proprietary and public databases.
Services
Unbiased quantitative proteomic analysis via high-resolution mass spectrometry for cell lines, organoids, tissues, and clinical samples with optimized processing protocols.
Tailored enrichment and analytical workflows to detect and quantify post-translational modifications and signaling events relevant to disease biology.
Integrated bioinformatics analysis using a proteomic database to identify biomarker signatures, mechanisms of resistance, and markers for patient selection.
Development and application of deep learning models that map proteomic readouts to predicted patient outcomes to inform clinical development and trial design.
Web-based portal for interrogation of experimental proteomic data in the context of internal and public databases to facilitate data exploration and decision making.
Unbiased quantitative proteomic analysis via high-resolution mass spectrometry for cell lines, organoids, tissues, and clinical samples with optimized processing protocols.
Tailored enrichment and analytical workflows to detect and quantify post-translational modifications and signaling events relevant to disease biology.
Integrated bioinformatics analysis using a proteomic database to identify biomarker signatures, mechanisms of resistance, and markers for patient selection.
Development and application of deep learning models that map proteomic readouts to predicted patient outcomes to inform clinical development and trial design.
Web-based portal for interrogation of experimental proteomic data in the context of internal and public databases to facilitate data exploration and decision making.
Expertise Areas
- Mass spectrometry–based proteomics
- Phosphoproteomics and PTM analysis
- Proteomic biomarker discovery
- Bioinformatics for proteomics
Key Technologies
- High-resolution mass spectrometry
- Phosphoproteomics
- Post-translational modification enrichment
- Proteomic databases
News & Updates
Mass-spectrometry-based proteomic profiling of human cancers to identify molecular subtypes and pathway features, classifying 532 cancers across six tissue types.
Deep proteomic profiling revealing mechanistic differences among medulloblastomas, defining higher risk subsets and potential therapeutic targets.
Unbiased analysis of breast tumor proteomes, quantifying 9995 proteins across tumors, recapitulating breast cancer molecular characterization.
Identification of colon cancer-associated proteins, neoantigens, and potential therapeutic targets, including Rb phosphorylation and glycolysis inhibition.
Mass-spectrometry-based proteomic profiling of human cancers to identify molecular subtypes and pathway features, classifying 532 cancers across six tissue types.
Deep proteomic profiling revealing mechanistic differences among medulloblastomas, defining higher risk subsets and potential therapeutic targets.
Unbiased analysis of breast tumor proteomes, quantifying 9995 proteins across tumors, recapitulating breast cancer molecular characterization.
Identification of colon cancer-associated proteins, neoantigens, and potential therapeutic targets, including Rb phosphorylation and glycolysis inhibition.